Search our Database of Scientific Publications and Authors

I’m looking for a

    2032 results match your criteria Neutrophilic Eccrine Hidradenitis

    1 OF 41

    Hidradenitis Suppurativa and Crohn's Disease: A Case Series.
    Ir Med J 2017 Aug 12;110(7):618. Epub 2017 Aug 12.
    Department of Dermatology, The Adelaide and Meath Hospital, Dublin.
    Hidradenitis Suppurativa (HS) is characterized by chronic recurrent abscesses, nodules and draining sinus tracts with scar formation. Cutaneous Crohn's Disease (CD) may also present similarly. We wished to identify and describe an Irish cohort with combined HS and CD, with a view to a better recognition of clinical manifestations and understanding of the pathophysiology underlying these two overlapping conditions. Read More


    Multiple Hypermetabolic Subcutaneous Lesions From Hidradenitis Suppurativa Mimicking Metastases on 18F-FDG PET/CT.
    Clin Nucl Med 2017 Nov 22. Epub 2017 Nov 22.
    Hidradenitis suppurativa is an inflammatory disease associated with subcutaneous nodules/abscesses that occur commonly in the axillary, inguinal, and perineal regions. We describe a case of a 64-year-old man presenting for F-FDG PET/CT for staging of a left vocal cord squamous cell carcinoma. The scan showed uptake in the left vocal cord malignancy and multiple hypermetabolic subcutaneous foci in the right axilla, right buttocks, and scalp in known locations of skin lesions related to hidradenitis suppurativa. Read More

    Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.
    Wounds 2017 Nov;29(11):E98-E102
    Objective: The objective of this study is to assess the rates of infection-free achievement of hidradenitis suppurativa clinical response (HiSCR) using integrated data from 2 phase 3, placebo-controlled trials, PIONEER I and II.

    Materials And Methods: Analyses from the first 12 weeks of both studies were examined. Patients were randomized to receive adalimumab (ADA) or placebo, and they then were assessed in the clinic at weeks 0, 2, 4, 8, and 12. Read More

    Correction to: Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa.
    Curr Pain Headache Rep 2017 Nov 18;21(12):52. Epub 2017 Nov 18.
    Ferkauf Graduate School of Psychology, Yeshiva University, 1165 Morris Park Avenue, Rousso Building, Bronx, NY, USA.
    The original version of this article contains an error in the spelling of the title. The title should read: Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa. Read More

    Response to "IL-36 in hidradenitis suppurativa: Evidence for a distinctive pro-inflammatory role and a key factor in the development of an inflammatory loop".
    Br J Dermatol 2017 Nov 18. Epub 2017 Nov 18.
    Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy.
    we read with interest the recent paper of Hessam et al.(1) regarding the involvement of IL-36 in hidradenitis suppurativa (HS). They have showed that agonist members of IL-36 were significantly overexpressed in HS lesional skin. Read More

    Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
    Curr Probl Dermatol 2018 7;53:49-63. Epub 2017 Nov 7.
    Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Paradoxical reactions during treatment with a biologic agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition, which usually remains under control (even though there may be a change in morphology or phenotype). Paradoxical reactions were initially described as isolated case reports or case series in patients treated with anti-tumor necrosis factor (TNF) α agents, first in inflammatory rheumatic diseases, later in psoriasis and inflammatory bowel disease. Paradoxical reactions have subsequently been reported with other biological drugs or classes (e. Read More

    Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
    Int J Dermatol 2017 Nov 11. Epub 2017 Nov 11.
    Department of Surgery, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
    Background: Hidradenitis supppurativa (HS) is a chronic inflammatory disease of the apocrine sweat glands affecting 1-4% of the population. While surgical excision is a mainstay of therapy, lesions often recur. Biologic therapies, including tumor necrosis factor-α and IL-12/23 inhibitors, are effective for mild to moderate HS. Read More

    MABp1 Targeting Interleukin-1Alpha for Moderate to Severe Hidradenitis Suppurativa not Eligible for Adalimumab: A Randomized Study.
    J Invest Dermatol 2017 Nov 9. Epub 2017 Nov 9.
    4(th) Department of Internal Medicine, National and Kapodistrian University of Athens, Greece. Electronic address:
    Background: Patients with moderate to severe hidradenitis suppurativa (HS) failing adalimumab therapy, or those ineligible to receive it, remain a population with an unmet need.

    Methods: 20 patients not eligible for adalimumab were randomized to receive 12 weeks blind treatment with placebo or MABp1, a true human antibody targeting interleukin (IL)-1alpha. HS clinical response score at week 12 was the primary endpoint. Read More

    A Cross-sectional Epidemiological Study of Hidradenitis Suppurativa in an Irish Population.
    J Eur Acad Dermatol Venereol 2017 Nov 10. Epub 2017 Nov 10.
    Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
    Background: Hidradenitis suppurativa (HS), a chronic inflammatory disease that affects apocrine gland-bearing skin, has a significant impact on patient quality of life. Estimates of the epidemiologic prevalence of HS are highly variable, and clinical data on disease characteristics and patient burden of disease remain limited.

    Objective: The primary objective of this study was to determine the number of patients with HS attending dermatology clinics in a hospital setting in Ireland (within a 6-month time period). Read More

    Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa.
    JAMA Dermatol 2017 Nov 8. Epub 2017 Nov 8.
    Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
    Importance: Hidradenitis suppurativa (HS) places a significant burden on the health-related quality of life (HRQOL) of patients, many of whom have depression. Resilience can play a role in mitigating the negative stressors, such as the symptoms of HS, on patients' mental health.

    Objective: To investigate the correlation among resilience, depression, and HRQOL for patients with HS. Read More

    [Acne inversa/hidradenitis suppurativa: A challenge for the future].
    Hautarzt 2017 Nov 6. Epub 2017 Nov 6.
    Interdisziplinäre Gruppe Molekulare Immunpathologie, Dermatologie/Med. Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
    Acne inversa (AI)/hidradenitis suppurativa is a chronic recurrent inflammatory dermatosis with signs of a systemic disease. AI is characterized by typical skin alterations in body areas bearing apocrine glands. The care of the AI patients in Germany is still inadequate. Read More

    Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    J Dermatolog Treat 2017 Nov 10:1-9. Epub 2017 Nov 10.
    d Department of Medicine, Division of Dermatology , University of Arizona , Tucson , AZ , USA.
    Purpose: Targeted, immune-modulating drugs are at the forefront of therapy for HS, and a comprehensive clinical trial registry is needed to facilitate data pooling and clinical efficacy comparison.

    Materials And Methods: A systematic review of the ClinicalTrials.gov database was searched for planned, in-progress, completed, or terminated trials investigating the effect of targeted biologic therapies for hidradenitis suppurativa (HS). Read More

    Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa.
    Br J Dermatol 2017 Nov 1. Epub 2017 Nov 1.
    Department of Dermatology & Academic Wound Healing, Division of Infection and Immunity, Cardiff University, Cardiff, CF14 4XN, UK.
    Background: Epidemiology data regarding hidradenitis suppurativa (HS) are conflicting and prevalence estimates vary 80-fold, from 0.05% in a population-based study, to 4%.

    Objectives: To assess the hypothesis that previous population-based studies under-estimated true HS prevalence by missing undiagnosed cases. Read More

    Pain, Psychological Comorbidities, Disability, and Impaired Qualify of Life in Hidradenitis Suppurativa.
    Curr Pain Headache Rep 2017 Nov 1;21(12):49. Epub 2017 Nov 1.
    Ferkauf Graduate School of Psychology, Yeshiva University, 1165 Morris Park Avenue, Rousso Building, Bronx, NY, USA.
    Purpose Of Review: Hidradenitis suppurativa (HS) is a chronic, painful dermatologic disease characterized by recurrent inflammatory nodules and abscesses of intertriginous areas such as the axilla and groin. People with HS suffer from greater pain and associated psychological comorbidities, including depression, anxiety, disability, and impairments in quality of life (QoL), compared to those with other dermatologic conditions. Our review focuses on the occurrence of pain and these relationships. Read More

    Towards global consensus on core outcomes for Hidradenitis Suppurativa research: An update from the HISTORIC consensus meetings I and II.
    Br J Dermatol 2017 Oct 28. Epub 2017 Oct 28.
    Department of Dermatology, Zealand University Hospital, Roskilde; Health Sciences Faculty, University of Copenhagen, Denmark.
    Background: A Core Outcomes Set (COS) is an agreed minimum set of outcomes that should be measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) has no agreed upon COS. A central aspect in the COS development process is to identify a set of candidate outcome domains from a long list of items. Read More

    Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis.
    J Am Acad Dermatol 2017 Oct 19. Epub 2017 Oct 19.
    Keck School of Medicine of the University of Southern California, Los Angeles, California. Electronic address:
    Background: The relationship between hidradenitis suppurativa and diabetes mellitus is not well understood.

    Objective: To compare the prevalence of diabetes mellitus between patients with and without hidradenitis suppurativa.

    Methods: We conducted a systematic review and meta-analysis, which included primary observational studies that reported the prevalence of diabetes mellitus among patients with hidradenitis suppurativa in the PubMed, Embase, Cochrane Library, LILACS, and Scielo databases from 1947 to June 13, 2017. Read More

    Hidradenitis Suppurativa: A Novel Model of Care and an Integrative Strategy to Adopt an Orphan Disease.
    J Cutan Med Surg 2017 Oct 1:1203475417736290. Epub 2017 Oct 1.
    1 Memorial University, St John's, Newfoundland, Canada.
    Unnecessary investigations, inappropriate treatment, worsening disease, and frustration for both patients and health care professionals are the hallmarks of hidradenitis suppurativa (HS) management. In light of a new treatment algorithm and biologic therapies made available to patients, an HS model of care is outlined in this article. The recommendations and management strategy presented here have been developed to help address the currently unmet needs of this patient population. Read More

    Self-reported minor infections in patients with hidradenitis suppurativa and healthy controls.
    Clin Exp Dermatol 2017 Oct 10. Epub 2017 Oct 10.
    Department of Dermatology, University Hospital Zealand, Roskilde, Denmark.
    Background: Patients with hidradenitis suppurativa (HS) often report opportunistic infections such as herpes and urinary tract infections.

    Aim: To compare opportunistic infections in patients with HS against a group of healthy controls (HCs).

    Methods: In total, 99 patients with HS and 109 HCs were recruited at random to this retrospective case-control study. Read More

    Preliminary Validation of the HS-QoL: A Quality-of-Life Measure for Hidradenitis Suppurativa.
    J Cutan Med Surg 2017 Oct 1:1203475417736281. Epub 2017 Oct 1.
    1 Department of Psychology, University of Windsor, Windsor, ON, Canada.
    Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with adverse physical and psychosocial impacts. The development of an HS quality-of-life measure, HS-QoL, has been recently described.

    Objective: This study was designed to validate the HS-QoL. Read More

    Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa.
    J Am Acad Dermatol 2017 Dec 6;77(6):1047-1052.e2. Epub 2017 Oct 6.
    Siaal Research Center for Family Medicine and Primary Care, Division of Community Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Quality Measurements and Research, Chief Physician's Office, Clalit Health Services, Tel-Aviv, Israel.
    Background: Data on the health care utilization of patients with hidradenitis suppurativa (HS) in primary care settings are scarce.

    Objective: To investigate the health care service utilization of patients with HS.

    Methods: In a cross-sectional study, patients with HS were compared with 2 age- and sex-matched control groups-general population enrollees of Clalit Health Services and a group of patients with psoriasis. Read More

    IL-36 in hidradenitis suppurativa: Evidence for a distinctive pro-inflammatory role and a key factor in the development of an inflammatory loop.
    Br J Dermatol 2017 Oct 4. Epub 2017 Oct 4.
    Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.
    Background: A possible regulatory involvement of the interleukin (IL)-36 family in inflammatory diseases has been suggested.

    Objectives: To analyze the expression of IL-36α, β, γ, and the antagonistic cytokines IL-36Ra, IL-37, and IL38 in the skin of hidradenitis suppurativa (HS) patients.

    Methods: Skin samples from lesional and corresponding perilesional HS skin, and from healthy controls were included in this study and analyzed by quantitative real-time RT-PCR. Read More

    Inherent differences in keratinocyte function in hidradenitis suppurativa: Evidence for the role of IL-22 in disease pathogenesis.
    Immunol Invest 2017 Oct 3:1-14. Epub 2017 Oct 3.
    a Division of Rheumatology , Ideas to Health Laboratory, School of Medicine and Health Sciences, The George Washington University , Washington , DC , USA.
    Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease of apocrine gland-bearing skin which affects approximately 1-4% of the population. Defective keratinocyte function has been postulated to play a role in HS pathogenesis. Using an in vitro scratch assay, differences between normal, HS, and chronic wound (CW) keratinocytes were evaluated. Read More

    Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa.
    Acta Derm Venereol 2017 Oct 3. Epub 2017 Oct 3.
    Department of Dermatology, Venereology and Allergology, Medical University, Chałubińskiego 1, PL-50-368 Wrocław, Poland.
    A growing body of research has indicated that pruritus is an important feature of hidradenitis suppurativa (HS). This study evaluated pruritus and pain among 103 patients with HS. Pruritus and pain intensity were assessed with a visual analogue scale, numerical rating scale and 4-item Itch Questionnaire. Read More

    Association between hidradenitis suppurativa and spondyloarthritis.
    Joint Bone Spine 2017 Sep 28. Epub 2017 Sep 28.
    Rheumatology Department, Maison-Blanche Hospital, Reims University Hospitals, 51092 Reims, France; Rheumatology Department, Le-Mans Hospital, 72037 Le Mans, France.
    Objectives: We aimed to investigate the existence of an association between hidrosadenitis suppurativa and spondyloarthritis.

    Methods: We performed a single-centre, cross-sectional study in patients with hidrosadenitis suppurativa followed in a tertiary care center, and in healthy volunteers without dermatological disease, matched for age (±5years) and gender. For each subject included, clinical examinations, HLA-B27 testing and sacro-iliac MRI were performed in order to diagnose spondyloarthritis according to the Assessment of SpondyloArthritis international Society (ASAS) criteria. Read More

    Resistance development to mycobacterum tuberculosis is manageable in hidradentis suppurativa. Response to Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?
    Br J Dermatol 2017 Sep 28. Epub 2017 Sep 28.
    Department of Dermatology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
    We read the letter by Mendes-Bastos et al. with concern.(1) Simply testing patients for latent tuberculosis solves the problem, and the authors did not mention that rifampin is an acceptable monotherapy for latent tuberculosis. Read More

    Incidence of Hidradenitis Suppurativa among Tobacco Smokers: a population based retrospective analysis in the United States.
    Br J Dermatol 2017 Sep 27. Epub 2017 Sep 27.
    Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY.
    Background: The relationship between tobacco use and hidradenitis suppurativa (HS) is controversial.

    Objective: To determine incidence of HS among tobacco smokers.

    Methods: Retrospective cohort analysis identifying incident HS cases among adult tobacco smokers and non-smokers sampled from a demographically heterogeneous population-based sample of over 50 million unique patients across all census regions. Read More

    Low Utilization of the Dermatology Ambulatory Encounter among Patients with Hidradenitis Suppurativa: A Population-Based Retrospective Cohort Analysis in the USA.
    Dermatology 2017 Sep 28. Epub 2017 Sep 28.
    Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA.
    Background: There are limited data evaluating the utilization of dermatologists for the care of patients with hidradenitis suppurativa.

    Objective: To determine the utilization of the dermatology ambulatory encounter among hidradenitis suppurativa patients, and to evaluate whether utilization varies by insurance status.

    Methods: This was a retrospective cohort analysis in an adult population sample of 42,030 hidradenitis suppurativa patients with either private or public health insurance who were identified by a validated scheme using SNOMED-CT terminology. Read More

    Acitretin Use in Dermatology.
    J Cutan Med Surg 2017 Nov/Dec;21(3_suppl):2S-12S. Epub 2017 Sep 27.
    9 University of Calgary, Calgary, AB, Canada.
    Background: Acitretin has been used for the treatment of severe psoriasis for over 20 years.

    Objective: The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation.

    Methods: A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. Read More

    Low and high body mass index in hidradenitis suppurativa patients-different subtypes?
    J Eur Acad Dermatol Venereol 2017 Sep 21. Epub 2017 Sep 21.
    Department of Dermatology, University Hospital Zealand, Roskilde, Denmark.
    Introduction: Overweight is a well-established risk factor for hidradenitis suppurativa (HS). In this cross-sectional study, we compare HS patients with a high body mass index (BMI) with HS patients with a low BMI to investigate differences in disease characteristics.

    Materials And Method: Patients were recruited from 17 dermatological centres from four continents. Read More

    Langerhans Cell Histiocytosis With Clinical and Histologic Features of Hidradenitis Suppurativa: Brief Report and Review.
    Am J Dermatopathol 2017 Sep 11. Epub 2017 Sep 11.
    Department of Dermatology, University of Florida College of Medicine, Gainesville, FL.
    Langerhans cell histiocytosis (LCH) is an uncommon histiocytic disorder in adults. Clinically, this rare entity can mimic other dermatologic conditions, including hidradenitis suppurativa. A case of LCH is reported with clinical and histologic features of hidradenitis suppurativa, along with a review of these unusual findings. Read More

    A phenotype combining hidradenitis suppurativa with Dowling-Degos disease caused by a founder mutation in PSENEN.
    Br J Dermatol 2017 Sep 18. Epub 2017 Sep 18.
    Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
    Dowling-Degos disease, featuring reticulate pigmentation, and familial hidradenitis suppurativa share many clinical features including autosomal dominant inheritance, flexural location and follicular defects. The co-existence of the two disorders was recently found to result from mutations in PSENEN, encoding protein presenilin enhancer gamma-secretase subunit. Here we report 4 additional families of Jewish Ashkenazi origin who presented with clinical features characteristic of both disorders. Read More

    Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa.
    J Am Acad Dermatol 2017 Dec 13;77(6):1038-1046. Epub 2017 Sep 13.
    Genesis Research, Hoboken, New Jersey. Electronic address:
    Background: Psoriasis and hidradenitis suppurativa (HS) exhibit distinct clinical features, but no studies have directly compared the health-related quality of life (HRQoL) in patients with moderate-to-severe manifestations of these conditions.

    Objective: To determine which disease is associated with more severe HRQoL impairment.

    Methods: Weighted averages of each of the following baseline HRQoL measures were determined and compared between HS and psoriasis populations from 5 clinical trials: Visual Analog Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index; EuroQOL 5D VAS, and Short Form-36 Health Survey. Read More

    Hidradenitis Suppurativa is Associated with Myocardial Infarction, but Not Stroke or Peripheral Arterial Disease of Lower Extremities.
    Br J Dermatol 2017 Sep 15. Epub 2017 Sep 15.
    Department of Dermatology, Roskilde Hospital, Køgevej 7-13, 4000, Roskilde.
    We performed a comparative cross-sectional study of the potential association of HS and the three outcome events: self-reported MI, self-reported stroke, and PAD measured by ankle-brachial index (ABI) ≤ 0.9. We included a self-reported HS group (n=430) identified in the general suburban population study (GESUS) using a validated questionnaire (2) (Table 1). Read More

    1 OF 41